[{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Epizyme \/ Pharmakon Advisors","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Pharmakon Advisors"},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Jefferies"},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"Methyltransferase","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Epizyme","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Epizyme"},{"orgOrder":0,"company":"Epizyme","sponsor":"Transcenta Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Epizyme \/ Epizyme","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Epizyme"},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Not Applicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ Ipsen"}]

Find Clinical Drug Pipeline Developments & Deals by Epizyme

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-inclass, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 12, 2022

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Ipsen

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2[1] inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 27, 2022

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Ipsen

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Treatment with Tazverik (tazemetostat) and R2 was generally well tolerated and the adverse events were consistent with those contained in the prescribing information for both tazemetostat and R2, respectively.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 02, 2022

                          Lead Product(s) : Tazemetostat,Rituximab,Lenalidomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TAZVERIK (tazemetostat), is a methyltransferase inhibitor of EZH21 is approved by the FDA for the treatment of certain patients with ES and certain patients with FL.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2022

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Hutchmed

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TST001 is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities and potent anti-tumor activities in tumor xenograft models.

                          Brand Name : TST001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 01, 2022

                          Lead Product(s) : TST001,Capecitabine,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Transcenta Holding

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : First patient dosed in the randomized portion of symphony-1 (EZH-302), epizyme’s phase 1B/3 confirmatory study of Tazverik (tazemetostat) in combination with rituximab + lenalidomide (R2) for the treatment of follicular lymphoma.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 15, 2022

                          Lead Product(s) : Tazemetostat,Lenalidomide,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Epizyme anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund global development and commercialization costs of tazemetostat outside of Japan.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 27, 2022

                          Lead Product(s) : Tazemetostat,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Jefferies

                          Deal Size : $85.0 million

                          Deal Type : Public Offering

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Among the 13 patients evaluated in this standard dose escalation design, no Dose Limiting Toxicities (DLTs) were observed during the first cycle of treatment up to the highest dose of 800mg of TAZVERIK twice daily.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 02, 2021

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The expanded loan facility is a part of the original loan agreement where Epizyme drew down $70 million to fund the regulatory milestones owed to Eisai for the New Drug Application submissions and U.S. FDA approvals of TAZVERIK® for epithelioid sarcoma ...

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 06, 2020

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Pharmakon Advisors

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Data supported the accelerated approval of TAZVERIK by the U.S. FDA for the treatment of epithelioid sarcoma in January 2020, and the accelerated approval of TAZVERIK by the FDA for the treatment of relapsed/refractory follicular lymphoma in June 2020.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 07, 2020

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank